Erbitux (Cetuximab)
Monoclonal Antibody for Colorectal Cancer and Head & Neck Cancer
Quick Facts About Erbitux
Key Takeaways About Erbitux
- Targeted cancer therapy: Erbitux specifically targets EGFR on cancer cells, blocking signals that promote tumour growth and spread in colorectal and head/neck cancers
- RAS testing is mandatory: For colorectal cancer, tumour RAS gene status must be confirmed as wild-type before treatment – Erbitux is ineffective in RAS-mutant tumours
- Skin reactions are very common: More than 80% of patients develop acne-like skin changes, which may correlate with treatment effectiveness
- Infusion reactions require monitoring: Patients must be observed during and for at least 1 hour after each infusion for allergic-type reactions
- Hospital-administered only: Erbitux is given as an intravenous infusion by trained healthcare professionals in a clinical setting
What Is Erbitux and What Is It Used For?
Erbitux (cetuximab) is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) on cancer cells. It is used to treat metastatic colorectal cancer and squamous cell carcinoma of the head and neck, either alone or in combination with chemotherapy and/or radiation therapy.
Erbitux contains the active substance cetuximab, which belongs to a class of drugs known as monoclonal antibodies. These are proteins that have been specifically engineered in a laboratory to recognise and bind to particular targets on the surface of cells. Cetuximab specifically binds to the epidermal growth factor receptor (EGFR), an antigen found on the surface of many cancer cells. EGFR plays a crucial role in promoting cancer cell growth, survival, and metastasis through a complex signalling cascade involving RAS proteins.
When cetuximab binds to EGFR, it blocks the receptor from receiving the growth signals that cancer cells need to proliferate and spread. This effectively shuts down the EGFR signalling pathway, preventing the cancer cells from growing and eventually leading to their death (apoptosis). Additionally, cetuximab can recruit immune cells to the tumour site through a process called antibody-dependent cell-mediated cytotoxicity (ADCC), where the body's immune system is directed to attack the cancer cells coated with cetuximab.
Metastatic Colorectal Cancer
Erbitux is approved for the treatment of metastatic colorectal cancer – cancer of the large bowel (colon or rectum) that has spread to other parts of the body. In this setting, Erbitux can be used either as a single agent (monotherapy) or in combination with chemotherapy regimens such as FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) or FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin). Clinical trials, including the landmark CRYSTAL and OPUS studies, have demonstrated that adding cetuximab to chemotherapy significantly improves response rates and overall survival in patients with wild-type RAS tumours.
It is critically important that patients with metastatic colorectal cancer undergo RAS gene testing before starting treatment with Erbitux. The RAS genes (KRAS and NRAS) encode proteins that are part of the EGFR signalling pathway. If the tumour carries a mutation in any of these RAS genes, the pathway remains active regardless of whether EGFR is blocked, rendering Erbitux ineffective. Moreover, studies have shown that patients with RAS-mutant tumours who receive Erbitux in combination with oxaliplatin-based chemotherapy may actually have worse outcomes than those receiving chemotherapy alone. Therefore, Erbitux should only be used in patients with confirmed wild-type RAS colorectal cancer.
Squamous Cell Carcinoma of the Head and Neck
Erbitux is also indicated for the treatment of squamous cell carcinoma of the head and neck (SCCHN). This includes cancers of the oral cavity, oropharynx, hypopharynx, and larynx. In locally advanced disease, Erbitux is used in combination with radiation therapy. The pivotal Bonner trial demonstrated that adding cetuximab to radiotherapy significantly improved overall survival and locoregional control compared to radiotherapy alone, without substantially increasing the radiation-related side effects.
In recurrent or metastatic SCCHN, Erbitux is used in combination with platinum-based chemotherapy (cisplatin or carboplatin) and 5-fluorouracil, as established by the EXTREME trial. This combination has been shown to improve both progression-free survival and overall survival. Erbitux may also be used as a single agent in patients whose platinum-based chemotherapy has failed, offering an additional line of treatment for those with limited options.
Erbitux was first approved by the European Medicines Agency (EMA) in 2004 and by the US Food and Drug Administration (FDA) in the same year. It is manufactured by Merck KGaA (Darmstadt, Germany) and distributed in various countries worldwide. Cetuximab was one of the first targeted therapies developed for colorectal cancer and has fundamentally changed the treatment landscape for this disease.
What Should You Know Before Receiving Erbitux?
Before starting Erbitux, your oncologist must verify your tumour's RAS gene status (for colorectal cancer), assess your risk of infusion reactions, and evaluate your overall health status. Several important contraindications and warnings must be considered before treatment begins.
Contraindications
You should not receive Erbitux if any of the following apply to you:
- History of severe hypersensitivity (allergic reaction) to cetuximab – patients who have previously experienced a severe or life-threatening infusion reaction to cetuximab must not receive it again
- RAS-mutant metastatic colorectal cancer with oxaliplatin: Erbitux must not be given in combination with oxaliplatin-containing chemotherapy if the tumour carries RAS mutations, as studies have shown detrimental outcomes in this population
Warnings and Precautions
Talk to your oncologist before receiving Erbitux if any of the following situations apply to you. These do not necessarily prevent treatment but require special monitoring or precautionary measures:
Infusion-related reactions: Erbitux can cause infusion-related side effects, which may be allergic (anaphylactic) in nature. These reactions typically occur during the infusion, within 1 hour afterwards, or occasionally later. For this reason, your condition will be monitored during every infusion of Erbitux and for at least 1 hour after each treatment. You will receive pre-medication with an antihistamine before the first dose to reduce the risk of an allergic reaction.
Higher risk of severe allergic reactions: Research has identified that patients who are allergic to red meat, have experienced tick bites, or test positive for certain antibodies (alpha-Gal IgE antibodies) may have an increased risk of severe allergic reactions to cetuximab. If any of these risk factors apply to you, your oncologist will discuss appropriate precautions and closely monitor you during treatment.
Skin reactions: Erbitux commonly causes skin side effects, including an acne-like rash. Your doctor will discuss whether preventive measures or early treatment of skin symptoms is necessary. Detailed information about skin reactions is provided in the side effects section below.
Heart problems: If you have existing cardiovascular disease, your oncologist will carefully assess whether you should receive Erbitux in combination with chemotherapy, particularly if you are 65 years of age or older. When used with fluoropyrimidine-containing chemotherapy, there is an increased risk of cardiac events.
Eye problems: Inform your doctor if you experience acute or worsening eye symptoms such as blurred vision, eye pain, red eyes, or severely dry eyes, or if you have had such problems in the past or use contact lenses. Your doctor may refer you to an ophthalmologist.
Low white blood cell count: If you receive Erbitux in combination with platinum-containing chemotherapy, the risk of a decrease in white blood cells is increased. Your doctor will monitor your blood counts and general condition for signs of infection.
Before treatment for metastatic colorectal cancer, your doctor must test your cancer cells to determine whether they contain wild-type (normal) or mutated RAS genes. You must not receive Erbitux in combination with oxaliplatin-containing chemotherapy if your cancer cells contain mutated RAS. This testing is a mandatory requirement before treatment can begin.
Pregnancy and Breastfeeding
If you are pregnant or suspect you may be pregnant, you must inform your doctor before starting treatment with Erbitux. The EGFR receptor is known to be involved in foetal development, and blocking it with cetuximab may potentially cause harm to the developing baby. Your oncologist will carefully discuss the risks and benefits of using Erbitux during pregnancy, taking into account the severity of your cancer and the available treatment alternatives.
Women of childbearing potential should use effective contraception during treatment with Erbitux and discuss family planning with their oncologist. You should not breastfeed during treatment with Erbitux. After receiving your last dose, you should wait at least two months before starting to breastfeed, as cetuximab may pass into breast milk and could potentially affect the nursing infant.
Children and Adolescents
There is no relevant use of Erbitux in children and adolescents. The safety and efficacy of cetuximab in patients under 18 years of age have not been established, and it is not indicated for any paediatric cancers.
Driving and Operating Machinery
Do not drive or operate machinery if you experience treatment-related symptoms that affect your ability to concentrate or react. Symptoms such as fatigue, dizziness, or visual disturbances may impair your ability to drive safely. Discuss with your oncologist whether it is safe for you to drive during your treatment period.
How Does Erbitux Interact with Other Drugs?
Erbitux is used in combination with specific chemotherapy regimens. The main interactions to be aware of involve platinum-based agents (oxaliplatin, cisplatin), fluoropyrimidines (5-FU, capecitabine), and irinotecan. Always inform your oncologist about all medications you are taking.
Unlike many small-molecule drugs, cetuximab is a monoclonal antibody that is not metabolised by liver enzymes (cytochrome P450 system). Instead, it is catabolised (broken down) by the reticuloendothelial system. This means that cetuximab has fewer traditional drug-drug interactions than many other medications. However, when used in combination with chemotherapy, the side effect profiles of both agents may overlap or interact, which is clinically important.
Combination Therapy Effects
| Drug/Regimen | Type | Effect | Clinical Consideration |
|---|---|---|---|
| Oxaliplatin | Platinum chemotherapy | Contraindicated with Erbitux in RAS-mutant tumours; may worsen outcomes | RAS testing mandatory; use only in wild-type RAS colorectal cancer |
| Irinotecan (FOLFIRI) | Topoisomerase inhibitor | Synergistic anti-tumour effect; increased diarrhoea risk | Standard combination; monitor for severe diarrhoea and neutropenia |
| Cisplatin / Carboplatin | Platinum chemotherapy | Increased risk of low white blood cell count; additive renal toxicity | Monitor blood counts, renal function, and signs of infection closely |
| Fluoropyrimidines (5-FU, capecitabine) | Antimetabolite | Increased risk of cardiac events (chest pain, heart attack, heart failure); hand-foot syndrome | Cardiac monitoring essential, especially in patients ≥65 years or with cardiac history |
| Radiation therapy | Radiotherapy | Increased mucositis, radiation-related skin reactions, difficulty swallowing, decreased white blood cells | Start Erbitux typically 1 week before radiation; proactive symptom management |
Tell your doctor about all medications you are currently taking, have recently taken, or might take, including over-the-counter medicines, vitamins, and herbal supplements. Although cetuximab does not have extensive pharmacokinetic drug interactions, your overall treatment plan must be coordinated to minimise overlapping toxicities and maximise therapeutic benefit.
When Erbitux is given in combination with other cancer medicines, those medicines must be administered at least 1 hour after the Erbitux infusion has been completed. This timing is important to minimise the risk of interactions between the infused drugs and to allow monitoring for any infusion-related reactions from cetuximab.
What Is the Correct Dosage of Erbitux?
Erbitux is given as an intravenous infusion by a qualified oncologist. The dose is calculated based on body surface area (BSA). Weekly dosing uses an initial dose of 400 mg/m² followed by 250 mg/m². Bi-weekly dosing uses a flat dose of 500 mg/m². Pre-medication with an antihistamine is required.
A doctor experienced in the use of anticancer medicines will supervise your treatment with Erbitux. During each infusion and for at least 1 hour afterwards, your condition will be regularly monitored to detect early signs of possible infusion-related side effects. You will be given an antihistamine medication before your first dose to reduce the risk of an allergic reaction.
Weekly Dosing Schedule
The weekly dosing schedule is used for both metastatic colorectal cancer and squamous cell carcinoma of the head and neck:
Initial Dose (Week 1)
400 mg/m² body surface area, administered as an intravenous infusion over approximately 2 hours. The maximum infusion rate must not exceed 10 mg/min.
Subsequent Doses (Week 2 onwards)
250 mg/m² body surface area, administered as an intravenous infusion over approximately 1 hour. The maximum infusion rate must not exceed 10 mg/min.
Bi-weekly (Every Two Weeks) Dosing Schedule
An alternative bi-weekly dosing schedule may be used for both indications when combined with other cancer treatments:
Every 2 Weeks
500 mg/m² body surface area, administered as an intravenous infusion over approximately 2 hours. The maximum infusion rate must not exceed 10 mg/min. This dose applies to both the first and all subsequent infusions.
Treatment Duration
Erbitux is typically given once a week or every two weeks. The duration of treatment varies depending on your type of cancer, the treatment combination being used, and how you respond to the therapy. Your oncologist will discuss how long your treatment course is expected to last and will regularly assess whether to continue or stop treatment based on your response and tolerability.
When used in combination with radiation therapy for head and neck cancer, treatment with Erbitux is typically started one week before radiation therapy begins and continued for the duration of the radiotherapy course. When used in combination with chemotherapy, the scheduling of Erbitux is coordinated with the chemotherapy cycle. The other cancer medicines must be given at least 1 hour after the Erbitux infusion is completed.
Dose Adjustments
Your doctor may need to adjust your Erbitux dose or delay treatment in certain situations:
- Skin reactions: If you develop severe skin reactions, your doctor may reduce the dose, delay the next infusion, or discontinue treatment. The decision depends on the severity and whether the reactions recur after dose reduction
- Infusion reactions: If you experience a mild to moderate infusion reaction, the infusion rate may be reduced. If you experience a severe infusion reaction, Erbitux must be permanently discontinued
- Low magnesium levels: Your doctor will monitor your magnesium levels and supplement as needed, without necessarily adjusting the Erbitux dose
Missed Dose
As Erbitux is administered in a hospital or clinic setting by healthcare professionals, missed doses are uncommon. If a scheduled infusion is delayed or missed for any reason, your oncologist will determine the best time to resume treatment. There is no need to “double up” on doses.
What Are the Side Effects of Erbitux?
The most common side effects of Erbitux are skin reactions (more than 80% of patients) and infusion-related reactions (more than 10% of patients). Other common side effects include mucositis, low magnesium levels, elevated liver enzymes, headache, fatigue, and diarrhoea.
Like all medicines, Erbitux can cause side effects, although not everyone experiences them. The two main categories of side effects are infusion-related reactions and skin reactions. Your oncologist will discuss the expected side effects with you before treatment begins and will monitor you closely throughout your treatment course.
Infusion-Related Reactions
Infusion-related reactions are among the most important side effects of Erbitux. More than 10 in 100 patients are expected to experience some form of infusion-related reaction, and in more than 1 in 100 patients these reactions are expected to be severe. These reactions may be allergic (anaphylactic) in nature and typically occur during the infusion, within 1 hour afterwards, or occasionally later.
Mild to moderate infusion reactions may include fever, chills, dizziness, and breathing difficulties. If you experience any of these symptoms, inform your healthcare team as soon as possible. They may slow the infusion rate to manage these symptoms.
Severe infusion reactions may include severe breathing difficulties that develop rapidly, hives (urticaria), fainting, and chest pain (which may indicate cardiac side effects). These reactions can have serious consequences, including life-threatening conditions in rare cases, and require immediate medical intervention. Treatment with Erbitux must be permanently discontinued if a severe infusion reaction occurs.
Skin Reactions
Skin reactions are the most frequently observed side effects of Erbitux, affecting more than 80 in 100 patients. In approximately 15 in 100 patients, these skin reactions are expected to be severe. Most skin reactions develop during the first three weeks of treatment and typically resolve over time after Erbitux treatment is stopped.
The main skin side effects include acne-like skin changes (papulopustular rash), itching (pruritus), dry skin (xerosis), skin scaling, increased hair growth (hypertrichosis), and nail disorders such as inflammation of the nail bed (paronychia). In very rare cases (up to 1 in 10,000 patients), blistering or skin peeling may occur, which could indicate a serious skin reaction called Stevens-Johnson syndrome – a potentially life-threatening condition requiring immediate medical attention.
Clinical studies have demonstrated a correlation between the severity of the acne-like skin rash and treatment outcomes. Patients who develop a more prominent rash tend to have better tumour response rates and longer survival. However, the rash should still be managed proactively with appropriate skin care to prevent secondary infections and maintain quality of life. Your oncologist will provide guidance on skin care during treatment.
Side Effects by Frequency
Very Common
- Skin reactions (acne-like rash, itching, dry skin, scaling, nail disorders)
- Infusion-related reactions (fever, chills, dizziness, breathing difficulties)
- Mucositis (inflammation of mucous membranes in the gut, mouth and nose, which may lead to nosebleeds)
- Low magnesium levels in the blood (hypomagnesaemia)
- Elevated liver enzyme levels
Common
- Headache
- Fatigue
- Eye irritation and redness (conjunctivitis)
- Diarrhoea
- Dehydration (may result from diarrhoea or reduced fluid intake)
- Nausea
- Vomiting
- Loss of appetite leading to weight loss
- Low calcium levels in the blood (hypocalcaemia)
Uncommon
- Blood clots in leg veins (deep vein thrombosis)
- Blood clots in the lungs (pulmonary embolism)
- Inflammation of the eyelid or outer layer of the eye
- Interstitial lung disease (inflammation of the lungs that may be life-threatening)
Very Rare
- Stevens-Johnson syndrome (severe blistering and peeling of the skin – life-threatening)
- Toxic epidermal necrolysis
Frequency Not Known
- Aseptic meningitis (inflammation of the membranes surrounding the brain)
Side Effects When Used with Other Cancer Treatments
When Erbitux is given in combination with other cancer medicines, some of the side effects you experience may be due to the combination or to the other medicines themselves. The following additional risks have been identified with specific combinations:
With platinum-containing chemotherapy (cisplatin, carboplatin, oxaliplatin): The likelihood of low white blood cell counts is increased. This can lead to infectious complications, including life-threatening conditions, particularly in patients who also have skin reactions, mucositis, or diarrhoea. If you develop general signs of infection, such as fever and fatigue, contact your doctor immediately.
With fluoropyrimidine-containing chemotherapy (5-FU, capecitabine): The likelihood of the following side effects increases – chest pain, heart attack, heart failure, and hand-foot syndrome (redness and swelling of the palms and soles, which may cause skin peeling).
With radiation therapy: Side effects typical for this combination may include worsened mucositis, radiation-related skin reactions, difficulty swallowing (dysphagia), and a decrease in white blood cells.
How Should Erbitux Be Stored?
Erbitux must be stored in a refrigerator at 2°C to 8°C. It does not contain preservatives and must be used immediately after opening. Storage is managed by hospital pharmacy staff – patients do not need to store this medication at home.
Erbitux must be stored at controlled refrigerator temperature between 2°C and 8°C (36°F to 46°F). The vials should be kept in the original packaging to protect from light. Do not use Erbitux after the expiry date stated on the label and carton after “EXP”. The expiry date refers to the last day of the stated month.
Since Erbitux is administered in a hospital or clinic setting, storage is managed by the hospital pharmacy. The product does not contain any antimicrobial preservative or bacteriostatic agent and is therefore intended for immediate use once opened. Once prepared for infusion, the diluted solution is chemically and physically stable for up to 48 hours at 25°C, but should be used as soon as possible to maintain sterility.
Keep all medicines out of the sight and reach of children. Do not throw away any medicines via household waste. Ask your pharmacist how to dispose of medicines you no longer use, as these measures help protect the environment.
What Does Erbitux Contain?
Erbitux contains cetuximab as the active substance at a concentration of 5 mg/ml. It is available in 20 ml vials (100 mg) and 100 ml vials (500 mg). The other ingredients include sodium chloride, glycine, polysorbate 80, citric acid monohydrate, sodium hydroxide, and water for injections.
Active Substance
The active substance is cetuximab. Each millilitre of the solution for infusion contains 5 mg of cetuximab. One 20 ml vial contains 100 mg of cetuximab. One 100 ml vial contains 500 mg of cetuximab.
Other Ingredients (Excipients)
The other ingredients in Erbitux are:
- Sodium chloride – used to adjust the tonicity of the solution
- Glycine – acts as a stabiliser for the protein
- Polysorbate 80 – a surfactant that helps prevent protein aggregation
- Citric acid monohydrate – acts as a buffer to maintain pH
- Sodium hydroxide – used for pH adjustment
- Water for injections – the solvent
Appearance and Pack Sizes
Erbitux 5 mg/ml solution for infusion is a clear to slightly opalescent, colourless to slightly yellow liquid supplied in glass vials. It is available in two vial sizes: 20 ml (containing 100 mg cetuximab) and 100 ml (containing 500 mg cetuximab). Each pack contains 1 vial. Not all vial sizes may be marketed in all countries.
The marketing authorisation holder is Merck Europe B.V., Amsterdam, Netherlands. The manufacturer is Merck Healthcare KGaA, Darmstadt, Germany.
Frequently Asked Questions About Erbitux
Erbitux (cetuximab) is used to treat two types of cancer: metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body) and squamous cell carcinoma of the head and neck. For colorectal cancer, it is used either alone or with chemotherapy, but only in patients whose tumours have wild-type (non-mutated) RAS genes. For head and neck cancer, it is used in combination with radiation therapy or chemotherapy. Erbitux works by blocking a receptor called EGFR on cancer cells, preventing them from receiving growth signals.
The most common side effects of Erbitux are skin reactions (affecting more than 80% of patients) and infusion-related reactions (affecting more than 10% of patients). Skin reactions include an acne-like rash, itching, dry skin, and nail problems. Infusion-related reactions can include fever, chills, dizziness, and breathing difficulties. Other common side effects include mucositis (inflammation of mucous membranes), low magnesium levels, headache, fatigue, diarrhoea, nausea, and loss of appetite. Most side effects are manageable with appropriate supportive care.
RAS testing is mandatory before starting Erbitux for metastatic colorectal cancer because the drug only works in patients whose tumours have wild-type (non-mutated) RAS genes. The RAS protein is part of the EGFR signalling pathway. If the tumour carries a RAS mutation, the signalling pathway remains active regardless of EGFR blockade, making Erbitux ineffective. Furthermore, studies have shown that patients with RAS-mutant tumours treated with Erbitux plus oxaliplatin-based chemotherapy may actually have worse outcomes than those treated with chemotherapy alone.
Erbitux is given as an intravenous infusion (drip) in a hospital or clinic. With weekly dosing, the first dose (400 mg/m²) takes about 2 hours, and subsequent doses (250 mg/m²) take about 1 hour each. With bi-weekly dosing, each dose (500 mg/m²) takes about 2 hours. Before the first dose, you will receive an antihistamine to reduce the risk of allergic reactions. You will be monitored during each infusion and for at least 1 hour afterwards. The total time at the clinic per session is typically 3–4 hours including preparation and monitoring.
Yes, Erbitux can cause severe infusion-related reactions that may be allergic (anaphylactic) in nature. Severe reactions are seen in more than 1 in 100 patients and can include difficulty breathing, hives, fainting, and chest pain. In rare cases, these can be life-threatening. Patients with known allergies to red meat, previous tick bites, or positive alpha-Gal antibody tests are at higher risk. Pre-medication with antihistamines is given to help prevent reactions, and patients are monitored during and after every infusion. If a severe reaction occurs, treatment with Erbitux must be permanently stopped.
Research suggests a correlation between the severity of the acne-like skin rash and treatment outcomes – patients who develop a more prominent rash tend to have better response rates and longer survival. This association has been observed in multiple clinical studies. However, the rash should still be managed with appropriate skin care, moisturisers, and sometimes antibiotics or topical treatments to prevent infections and maintain quality of life. The absence of a rash does not necessarily mean the treatment is not working, but your oncologist may consider this factor when assessing your treatment response.
References
- European Medicines Agency (EMA). Erbitux – Summary of Product Characteristics. Updated January 2026. Available at: EMA – Erbitux
- Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology. 2016;27(8):1386–1422. doi:10.1093/annonc/mdw235
- Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine. 2006;354(6):567–578. doi:10.1056/NEJMoa053422
- Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer (CRYSTAL trial). New England Journal of Medicine. 2009;360(14):1408–1417. doi:10.1056/NEJMoa0805019
- Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer (EXTREME trial). New England Journal of Medicine. 2008;359(11):1116–1127. doi:10.1056/NEJMoa0802656
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology – Colon Cancer, Version 1.2026.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology – Head and Neck Cancers, Version 1.2026.
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List, 2023.
- US Food and Drug Administration (FDA). Erbitux Prescribing Information. Available at: FDA – Erbitux Label
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which includes licensed specialist physicians in oncology, clinical pharmacology, and internal medicine. All medical content follows international clinical guidelines (WHO, EMA, NCCN, ESMO) and is graded according to the GRADE evidence framework.
Content created by iMedic’s medical editors with expertise in oncology and pharmacology, based on approved product information and peer-reviewed clinical trial data.
Independently reviewed by the iMedic Medical Review Board according to international oncology guidelines and current evidence-based practice standards.
Level 1A evidence based on systematic reviews and randomised controlled trials (CRYSTAL, OPUS, Bonner, EXTREME). All claims are referenced to peer-reviewed sources.
iMedic receives no commercial funding from pharmaceutical companies. All editorial content is produced independently without industry influence or advertising sponsorship.